Genting Int Poker

BB bluffing retail buyers

Retail buyers took the bets

Yangzijiang 5 mins chart Bottom Searching

Gapped down at opening from $1.31 to $1.25.

Failed to form bottom at $1.17.

Wait for base formation.

Oligo Manufacturing Puts Emphasis on RNA

As more experimental DNA drugs move through the clinic and into large-scale trials, the demand for efficient and cost-effective manufacturing strategies is intensifying. Higher yields, greater purity, and lower production costs are the key drivers of new DNA synthesis technology. Similarly, as both therapeutic and research applications of RNA oligos increase dramatically, competition and price pressure are driving advances in RNA synthesis technology as well.

Although there has "not been a lot of good news in the last 12 months or so from an antisense DNA perspective, there are still plenty of promising second-generation chemistry drugs that are in the clinic and are progressing," says Gaby Silver, marketing manager at Kinovate Life Sciences, a new company solely held by Osaka, Japan-based Nitto Denko.

At the recent "TIDES" meeting, in Boston, Kinovate launched NittoPhase™, a novel solid support for oligo synthesis developed in collaboration with Isis Pharmaceuticals. The product is available in two grades: NittoPhaseTOS for high loading applications and NittoPhaseROS, composed of a bead with a lower loading capacity.

http://www.genengnews.com/oligo/oligo_supp_02.aspx

How Can Someone Patent a Gene?

Crichton and other critics often ask, “How can anyone own my genes?” The answer is that they cannot. What someone can “own” is a DNA sequence that he or she was the first to isolate and that is useful. Similarly, a person who discovers a new function of a known DNA sequence, such as its previously unknown association with particular disease, can patent a method of using the isolated sequence to detect susceptibility to that disease. Isolated DNA sequences do not occur in nature. They are new.

Claiming them as isolated sequences is not “mere word play” as asserted by Congressman Becerra in his remarks. Rather, the language reflects the critical fact that, but for the actions of the inventor, the invention would not exist. The gene for human Factor VIII doesn’t do a hemophiliac any good when it is in somebody else’s genome. It is only useful when someone isolates it and a company spends time and money to bring human Factor VIII to the market. Since isolated DNA sequences do not occur in nature, they are not natural products. By patenting them, the inventor takes nothing from the public.

http://www.genengnews.com/articles/chitem.aspx?aid=2052

Stem Cell Research

Along these same lines, stem cell research will also add to the robust growth of the cell culture market. The growing use and diverse applications of stem cells are having a significant impact on the media market, as companies work to understand how best to optimize and influence their growth. For stem cell applications, serum-free media that lack growth factors, cytokines, or artificial stimulators of proliferation will play an increasingly important role.

The expected growth in the stem cell market provides a tremendous growth opportunity. Kalorama estimates that stem cell research accounted for nearly $1 billion million in expenditures last year, 10% of which was allocated to consumables, and about 5% of the consumable allocation was spent on media and other cell culture supplies. In addition, media and serum used in stem cell research are priced higher than similar, non-stem cell products.

Multiple licensing agreements and acquisitions have been made in the cell culture market by numerous companies in order to secure a foothold in the stem cell supply market .

http://www.genengnews.com/articles/chitem.aspx?aid=2086

Yongnam Near Major Support

Monitor 200EMA weekly support.